Filtered By:
Therapy: Corticosteroid Therapy
Countries: Japan Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 22 results found since Jan 2013.
New-onset dermatomyositis following COVID-19: A case report
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the infected individuals have recovered without complications, but a few patients develop multiple organ involvements. Previous reports suggest an association between COVID-19 and various inflammatory myopathies, in addition to autoimmune diseases. COVID-19 has been known to exacerbate preexisting autoimmune diseases and trigger various autoantibodies and autoimmune disease occurrence. Here we report a case of complicated COVID-19 with anti-synthetase autoantibodies (ASSs) presenting ...
Source: Frontiers in Immunology - October 24, 2022 Category: Allergy & Immunology Source Type: research
Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry
ConclusionsThis study described clinical characteristics of COVID-19 patients with rheumatic diseases in Japan. Several possible risk factors for severe COVID-19 progression were suggested.Key points•Clinical characteristics of 222 adult patients in Japan with coronavirus disease 19 (COVID-19) and pre-existing rheumatic diseases were described.•Most patients were hospitalised (86.9%) for COVID-19 in Japan, 43.3% received oxygen, and 9.0% died.•The COVID-19 characteristics of patients with rheumatic diseases did not show any obvious different pattern from those of the general population in Japan.•In this study, olde...
Source: Clinical Rheumatology - August 16, 2022 Category: Rheumatology Source Type: research
U.S. FDA grants priority review to Roche ’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults
If approved,Actemra/RoActemra would be the first U.S. FDA-approvedimmunomodulator for the treatment of COVID-19 inhospitalised patientsSince the beginning of the pandemic, more than one million peoplehospitalised with COVID-19 have been treated withActemra/RoActemra worldwide1Actemra/RoActemra is approved for the treatment of COVID-19 in many territories including the European UnionRoche has established a comprehensive access approach to improve availability ofActemra/RoActemra around the worldBasel, 04 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has acce...
Source: Roche Investor Update - April 4, 2022 Category: Pharmaceuticals Source Type: news
Severe Anemia Due to Cold Agglutinin Syndrome in a COVID-19 Patient with IgM Monoclonal Gammopathy of Undetermined Significance Successfully Treated with Corticosteroids
Intern Med. 2022 Mar 26. doi: 10.2169/internalmedicine.8647-21. Online ahead of print.ABSTRACTSecondary cold agglutinin syndrome (CAS) is autoimmune hemolytic anemia secondary to infections and lymphoid disorder. We here report the first Asian case of CAS secondary to novel coronavirus disease 2019 (COVID-19). A 72-year-old Japanese woman presented with a 2-week history of dyspnea and cough, and laboratory data revealed severe hemolytic anemia with a hemoglobin level of 4.7 g/dL. She was diagnosed with COVID-19, CAS, and monoclonal gammopathy of undetermined significance (MGUS). The anemia responded to corticosteroids admi...
Source: Internal Medicine - March 28, 2022 Category: Internal Medicine Authors: Yutaka Tsukamoto Masataka Umeda Yuko Muto Takashi Sugimoto Momoko Yamauchi Koji Ando Koya Ariyoshi Source Type: research
Multisystem Inflammatory Syndrome in Adult after First Dose of mRNA Vaccine
Emerg Infect Dis. 2022 Feb 11;28(4). doi: 10.3201/eid2804.212585. Online ahead of print.ABSTRACTA 32-year-old man in Japan experienced respiratory failure after receiving the first dose of coronavirus disease (COVID-19) vaccine. He was treated with noninvasive ventilation and corticosteroids. Serologic test results suggested previous COVID-19; therefore, he received a diagnosis of multisystem inflammatory syndrome. COVID-19 vaccination could be a trigger for this condition.PMID:35148495 | DOI:10.3201/eid2804.212585
Source: Emerging Infectious Diseases - February 11, 2022 Category: Infectious Diseases Authors: Yusuke Miyazato Kei Yamamoto Gen Yamada Shuji Kubota Masahiro Ishikane Masaya Sugiyama Mikako Ueno Akihiro Matsunaga Tohru Miyoshi-Akiyama Yukihito Ishizaka Norio Ohmagari Source Type: research
Decrease of infectious complications in outpatients with autoimmune diseases from 2019 to 2020 under the COVID-19 pandemic: A single-centre, retrospective cohort study in Japan
CONCLUSION: Under the COVID-19 pandemic, some infectious complications have decreased in outpatients with autoimmune diseases.PMID:34918128 | DOI:10.1093/mr/roab080
Source: Herpes - December 17, 2021 Category: Infectious Diseases Authors: Yumiko Oka Takao Kodera Miki Takeshita Yuko Shirota Tomoki Takeda Tomomi Tsutsumi Junichi Kameoka Source Type: research
Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient
Intern Med. 2021 Nov 20. doi: 10.2169/internalmedicine.8568-21. Online ahead of print.ABSTRACTA 57-year-old man without underlying diseases presented with fatigue, loss of appetite, and jaundice 1 week after receiving the first dose of the BNT162b2 mRNA coronavirus disease (COVID-19) vaccine and showed hemolytic anemia with fragmented erythrocytes and severe thrombocytopenia 2 weeks after receiving the vaccine. An ADAMTS13 activity level of <10% and ADAMTS13 inhibitor positivity confirmed the diagnosis of acquired thrombotic thrombocytopenic purpura (TTP). Combination therapy with plasma exchange, corticosteroid, and ri...
Source: Internal Medicine - November 22, 2021 Category: Internal Medicine Authors: Kikuaki Yoshida Ayaka Sakaki Yoriko Matsuyama Toshiki Mushino Masanori Matsumoto Takashi Sonoki Shinobu Tamura Source Type: research
